Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neurology|December 28, 2013
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trialFabienne Ory-Magne, Jean-Christophe Corvol, Jean-Philippe Azulay, et al.
Neurology|August 8, 2014
Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disordersSerena Lattante, Stéphanie Millecamps, Giovanni Stevanin, et al.
Archives of Neurology|March 14, 2007
LRRK2 exon 41 mutations in sporadic Parkinson disease in EuropeansSuzanne Lesage, Sabine Janin, Ebba Lohmann, et al.
Annals of Neurology|August 2, 2003
How much phenotypic variation can be attributed to parkin genotype?Ebba Lohmann, Magali Periquet, Vincenzo Bonifati, et al.
Plos One|September 9, 2016
Correction: Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical TrialAndreas Hartmann, Julia Muellner, Niklaus Meier, et al.
Plos One|July 13, 2016
Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical TrialAndreas Hartmann, Julia Müllner, Niklaus Meier, et al.
Neurology|March 21, 2014
Optimal target localization for subthalamic stimulation in patients with Parkinson diseaseMarie-Laure Welter, Michael Schüpbach, Virginie Czernecki, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2009
Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's diseaseJens Volkmann, Alberto Albanese, Jaime Kulisevsky, et al.
Pageof 4